JPH036790B2 - - Google Patents
Info
- Publication number
- JPH036790B2 JPH036790B2 JP57132790A JP13279082A JPH036790B2 JP H036790 B2 JPH036790 B2 JP H036790B2 JP 57132790 A JP57132790 A JP 57132790A JP 13279082 A JP13279082 A JP 13279082A JP H036790 B2 JPH036790 B2 JP H036790B2
- Authority
- JP
- Japan
- Prior art keywords
- urokinase
- starch
- conjugate
- hes
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229920002472 Starch Polymers 0.000 claims description 86
- 239000008107 starch Substances 0.000 claims description 86
- 229960005356 urokinase Drugs 0.000 claims description 81
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 75
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 74
- 235000019698 starch Nutrition 0.000 claims description 54
- 239000003527 fibrinolytic agent Substances 0.000 claims description 7
- 229960000103 thrombolytic agent Drugs 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 19
- 229940050526 hydroxyethylstarch Drugs 0.000 description 19
- 239000008280 blood Substances 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 230000002537 thrombolytic effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 239000012153 distilled water Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000008363 phosphate buffer Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 6
- -1 cyanoborohydride Chemical compound 0.000 description 6
- 239000003146 anticoagulant agent Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000002523 gelfiltration Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 3
- 102000009123 Fibrin Human genes 0.000 description 3
- 108010073385 Fibrin Proteins 0.000 description 3
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 229950003499 fibrin Drugs 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241001161843 Chandra Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- MYGMBVDLWDZOIL-UHFFFAOYSA-N methane;cyanide Chemical compound C.N#[C-] MYGMBVDLWDZOIL-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Landscapes
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57132790A JPS5922901A (ja) | 1982-07-28 | 1982-07-28 | ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57132790A JPS5922901A (ja) | 1982-07-28 | 1982-07-28 | ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5922901A JPS5922901A (ja) | 1984-02-06 |
| JPH036790B2 true JPH036790B2 (fr) | 1991-01-30 |
Family
ID=15089604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57132790A Granted JPS5922901A (ja) | 1982-07-28 | 1982-07-28 | ウロキナ−ゼ・デンプン結合物、その製造法及び血栓溶解剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5922901A (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2628310B2 (ja) * | 1987-08-31 | 1997-07-09 | 和光純薬工業株式会社 | 酵素の安定化方法 |
| EP0999222A1 (fr) * | 1998-11-02 | 2000-05-10 | Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno | Produits d'oxidation d'hydrates de carbone |
-
1982
- 1982-07-28 JP JP57132790A patent/JPS5922901A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5922901A (ja) | 1984-02-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI619510B (zh) | 因子ｖｉｉｉ聚合共軛物 | |
| CA1305665C (fr) | Compositions a macromolecules contenant du platine, pour le traitement des tumeurs | |
| CN101965200B (zh) | 缀合的因子ⅷ分子 | |
| EP0640622B1 (fr) | Derive de polysaccharide et vehicule de medicament | |
| JP7071093B2 (ja) | 血液凝固タンパク質複合体 | |
| JPH09506087A (ja) | 改良されたインターフェロン−ポリマー複合体 | |
| KR0184858B1 (ko) | 폴리믹신 복합체 | |
| JPH0429680B2 (fr) | ||
| EP0019403B1 (fr) | Support de médicament en hydroxyalkylamidon | |
| JP2001081103A (ja) | ヒアルロン酸結合薬剤 | |
| JPH036790B2 (fr) | ||
| JPH0215193B2 (fr) | ||
| US20190240295A1 (en) | Factor viii with extended half-life and reduced ligand-binding properties | |
| JPH02231078A (ja) | ヒアルロン酸修飾スーパーオキシドジスムターゼ | |
| RU2164149C2 (ru) | Конъюгаты полимиксина | |
| JPS6360938A (ja) | 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法 | |
| JPS6043116B2 (ja) | ウロキナ−ゼ誘導体 | |
| US20030236224A1 (en) | Modified polysaccharides exhibiting altered biological recognition | |
| JPH0143553B2 (fr) | ||
| JPS5920301A (ja) | ウロキナ−ゼ・デキストラン誘導体の製造法 | |
| JPH09124512A (ja) | 肝臓ターゲティングのための水溶性の薬物−プルラン結合体製剤 | |
| TWI310787B (en) | Antiangiogenic polypeptides and methods for inhibiting angiogenesis | |
| JPH02231077A (ja) | ヘパリン修飾スーパーオキシドジスムターゼ | |
| JPH02231076A (ja) | デキストラン修飾スーパーオキシドジスムターゼ | |
| JPS62142122A (ja) | ＨＢｓＡｇ複合体、その製造法およびＨＢワクチン |